Metamark Genetics has appointed Kenneth Weg as president and CEO. He succeeds Shawn Marcell, who resigned from his position to pursue other activities. Weg is a Metamark co-founder and current chairman of the board of directors. He has previously served as the president of the Worldwide Medicines Group at Bristol-Myers Squibb (BMS), where he was responsible for overseeing all ethical pharmaceuticals and over-the-counter medicines on a global basis. Weg also served as vice chairman of the BMS board of directors. Before his work at BMS, he held the position of non-executive chairman of Millennium Pharmaceuticals. He has also served on the boards of Fox Chase Cancer Center and AVEO Pharmaceuticals and is a current member of Karyopharm's board of directors.